Nuevolution Announces Strategic Collaboration with Amgen in Oncology and Neuroscience



Provides Amgen access to Nuevolution’s proprietary Chemetics® drug discovery platform to identify and develop novel therapeutics. Nuevolution is eligible to receive up to USD 410 million per development program and tiered royalties on future sales.

Nuevolution and Amgen have entered into a multiple target research collaboration to develop and commercialize novel therapeutics in the areas of oncology and neuroscience. Nuevolution will apply its Chemetics® drug discovery platform to discover and advance potential therapeutics of interest to Amgen. The research collaboration brings together Nuevolution’s proprietary drug discovery platform with Amgen’s disease expertise and drug development capabilities.

“We are excited about entering into this broad collaboration with Amgen,” said Alex Gouliaev, CEO of Nuevolution A/S and continued, “the agreement with Amgen represents an important business component for Nuevolution in its ambition to discover and develop new medicines for severe diseases, while also capitalizing on Nuevolution’s powerful drug discovery engine. We are looking forward to an excellent working relationship with Amgen’s dedicated research and development teams.”

Read the press release ↗